HCV
Conditions
Keywords
Daclatasvir, Sofosbuvir, Children, HCV, Pharmacokinetics, Safety, Efficacy, Acceptability
Brief summary
This is an interventional, single center, single arm clinical trial to assess the pharmacokinetics, safety, efficacy, and acceptability of daclatasvir plus sofosbuvir in treatment-naïve children weighing between 14 and 35 kg with chronic HCV GT 1-6 infection.
Detailed description
This is an interventional, single center, single arm clinical trial to assess the pharmacokinetics, safety, efficacy, and acceptability of daclatasvir plus sofosbuvir in treatment-naïve, children weighing between 14 and 35 kg with chronic HCV GT 1-6 infection. All enrolled patients will receive daclatasvir 30 mg orally once daily plus sofosbuvir at a dose of 200 mg (2x 100 mg tablets) orally once daily for 12 weeks. Patients will be followed closely for disease progression and any hypersensitivity or adverse reactions due to therapy. Laboratory values to be monitored at baseline are serum creatinine, bilirubin, Aspartate transaminase (AST), Alanine transaminase (ALT), viral load (VL). patients will be recruited in each of two weight bands (14 to \< 17 kg and 17 to 35 kg). The study is mainly powered for non-compartmental pharmacokinetics determination of DCV, SOF and GS-331007. Patient recruitment will be done at Ain Shams university hospitals, Egypt. The study be will conducted after approval by the corresponding research ethical committee and obtaining an informed consent from the parents or the legal guardians, and -whenever applicable- an assent from the patients. Total number of visits is 7 for patients who will complete the study, a screening visits, at the first day of therapy, at weeks 1, 4, 8, 12 and 24 after starting daclatasvir plus sofosbuvir. Patients who will complete their treatment schedule will come after 12 weeks for assessment of SVR. Duration of follow up will be 6 months from treatment initiation in addition to screening period (2-4 weeks).
Interventions
DRUGSofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets
Daclatasvir 30 mg orally once daily plus Sofosbuvir at a dose of 200 mg (2x 100 mg tablets) orally once daily for 12 weeks.
Sponsors
Cairo University
Ain Shams University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Children more than 3 years of age and weighing 14-35kg * Infected with HCV genotypes 1-6 * Treatment Naïve HCV-infected children * Signing a written consent form by the parent or the legal guardian, and -whenever applicable- an assent by the patient * Screening laboratory values within predefined thresholds: 1. Absolute neutrophil count ≥ 1,500/mm3 2. Platelets \> 50,000 cells/mm3 3. Albumin \> 3.5 mg/dL 4. Prothrombin Time PT \< 4 sec above control Or International Normalized Ratio INR \<1.7 3 5. Random blood glucose level within normal range (\> 70 mg/dL and \< 200 mg/dL) 6. Serum creatinine \< 1.5 mg/dL
Exclusion criteria
* Co-infection with HIV, acute hepatitis A virus, or hepatitis B virus * Clinical hepatic decompensation, i.e., Child-Turcotte-Pugh CTP class B or C (i.e., jaundice, ascites, encephalopathy, or variceal hemorrhage) * Renal dysfunction, i.e., eGFR \< 60 mL/min/1.73 m2 or on regular dialysis as calculated by Schwartz Formula * Alfa-fetoprotein level \> 50 ng/mL * Chronic liver disease due to a cause other than HCV or Known hypersensitivity to daclatasvir or sofosbuvir. * History of gastrointestinal disease or gastrointestinal surgical procedure that would impair the absorption of the study drug * Blood/blood product transfusion within 4 weeks prior to study. * Systemic corticosteroid administration for more than 2 weeks starting from two weeks before study inclusion and till the end of treatment period (pulmonary/nasal administration is permitted). * Psychiatric hospitalization, suicide attempt or disability resulting from psychiatric illness within the prior 5 years. * Ongoing treatment with any medications interacting with daclatasvir/sofosbuvir.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma concentration of Daclatasvir | one week | The plasma concentration of Daclatasvir on day 8 will be used to derive the Pharmacokinetic parameters using the Non-Compartmental analysis (NCA) |
| Plasma concentration of Sofosbuvir | one week | The plasma concentration of Daclatasvir on day 8 will be used to derive the Pharmacokinetic parameters using the Non-Compartmental analysis (NCA) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of Daclatasvir 30 MG oral tablets and Sofosbuvir 200 MG oral tablets once daily for 12 weeks | 24 weeks | Efficacy will be assessed via sustained virologic response at 12 weeks after the 12 weeks treatment completion (SVR12) |
| Safety of Daclatasvir 30 MG oral tablets and Sofosbuvir 200 MG oral tablets once daily for 12 weeks | 24 weeks | Safety o will be assessed by recording any adverse event occurs in treatment period and 2-4 weeks after the last visit (after week 24) |
Countries
Egypt
Contacts
Primary ContactManal H. El-Sayed, MD
Outcome results
None listed